DENVER – As part of Lung Cancer Awareness Month in November, the International Association for the Study of Lung Cancer (IASLC) today announced a new global initiative to create a set of Patient/Provider Lung Cancer Information Cards to create better communication and understanding between physicians, patients and their families with the goal of improving collaboration and better treatment outcomes around the world.

DENVER – The International Association for the Study of Lung Cancer (IASLC) commends the U.S. Food and Drug Administration’s (FDA) decision to grant accelerated approval for osimertinib (TagrissoTM), an oral medication for advanced non-small cell lung cancer (NSCLC) patients with a specific epidermal growth factor receptor (EGFR) mutation (T790M) and following progression after previous EGFR inhibitor therapies.

DENVER – During November’s Lung Cancer Awareness Month, the International Association for the Study of Lung Cancer (IASLC) wants to highlight the importance of immunotherapy, a form of personalized medicine and a groundbreaking tool in the fight against lung cancer.

DENVER – Sorafenib, a tyrosine kinase inhibitor (TKI) targeting the receptors for vascular endothelial growth factor, platelet derived growth factor, and mast/stem cell growth factor, modestly increases progression-free survival (PFS), time to progression, and disease control rate in non-small cell lung cancer (NSCLC) patients who have relapsed or failed two or three previous treatment regimens.

DENVER – November is Lung Cancer Awareness Month, but lung cancer does not have an awareness problem; lung cancer has a perception problem. What many people believe about lung cancer is inaccurate, and the International Association for the Study of Lung Cancer (IASLC) knows that if we can confront these myths, we can change misconceptions and help find cures for lung cancer.

October 2015 Newsletter

The pace of progress in lung cancer is truly amazing and gratifying. In the last few weeks one immunotherapy drug was approved for lung cancer in the USA and another received an expanded indication. We have exciting data on the activity of these agents in small cell lung cancer and mesothelioma presented at the WCLC, and another new drug in small cell presented first there and advancing in clinical trials. New genetic targets are showing their impact on targeted therapies.